Diagnosis and treatment of bradykinin-mediated angioedema: Outcomes from an angioedema expert consensus meeting

Timothy J. Craig, Jonathan A. Bernstein, H. Farkas, Laurence Bouillet, Isabelle Boccon-Gibod

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Several types of angioedema exist beyond hereditary angioedema (HAE) types I/II; however, the diagnostic and treatment needs of these conditions are not well understood. Noticeably, there are no licensed treatments available for other forms of angioedema beyond HAE types I/II, and similarly they are unresponsive to conventional antihistamine/glucocorticoid treatment. A group of angioedema experts met in Budapest in May 2013 to discuss such issues, presenting their experience, reviewing available literature and identifying unmet diagnostic and treatment needs in three different angioedema types: HAE with normal C1-inhibitor (C1-INH; previously referred to as type III HAE); nonallergic angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema (ACEI-AAE), and acquired angioedema due to C1-INH deficiency (C1-INH-AAE). The group identified unmet diagnostic and treatment needs in HAE-nC1-INH, C1-INH-AAE and ACEI-AAE, explored remedies and made recommendations on how to diagnose and treat these forms of angioedema. The group discussed the difficulties associated with using diagnostic markers, such as the level and function of C1-INH, C1q and C4 to reliably diagnose the angioedema type, and considered the use of genetic testing to identify mutations in FXII or XPNPEP2 that have been associated with HAE-nC1-INH and ACEI-AAE, respectively. Due to the lack of approved treatments for HAE-nC1-INH, ACEI-AAE and C1-INH-AAE, the group presented several case studies in which therapies approved for treatment of HAE types I/II, such as icatibant, ecallantide and pasteurized, nanofiltered C1-INH, were successful. It was uniformly agreed that further studies are needed to improve the diagnosis and treatment of angioedema other than HAE types I/II.

Original languageEnglish
Pages (from-to)119-127
Number of pages9
JournalInternational Archives of Allergy and Immunology
Volume165
Issue number2
DOIs
Publication statusPublished - Dec 25 2014

Fingerprint

Angioedema
Bradykinin
Hereditary Angioedema Types I and II
Hereditary Angioedemas
Angiotensin-Converting Enzyme Inhibitors
Hereditary Angioedema Type III
Histamine Antagonists
Genetic Testing
Glucocorticoids
Mutation

Keywords

  • Angioedema
  • C1 inhibitor
  • C1-esterase inhibitor
  • Hereditary angioedema
  • Treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Medicine(all)

Cite this

Diagnosis and treatment of bradykinin-mediated angioedema : Outcomes from an angioedema expert consensus meeting. / Craig, Timothy J.; Bernstein, Jonathan A.; Farkas, H.; Bouillet, Laurence; Boccon-Gibod, Isabelle.

In: International Archives of Allergy and Immunology, Vol. 165, No. 2, 25.12.2014, p. 119-127.

Research output: Contribution to journalArticle

Craig, Timothy J. ; Bernstein, Jonathan A. ; Farkas, H. ; Bouillet, Laurence ; Boccon-Gibod, Isabelle. / Diagnosis and treatment of bradykinin-mediated angioedema : Outcomes from an angioedema expert consensus meeting. In: International Archives of Allergy and Immunology. 2014 ; Vol. 165, No. 2. pp. 119-127.
@article{cb0df7ae55e946d5bfc378dd17cfc056,
title = "Diagnosis and treatment of bradykinin-mediated angioedema: Outcomes from an angioedema expert consensus meeting",
abstract = "Several types of angioedema exist beyond hereditary angioedema (HAE) types I/II; however, the diagnostic and treatment needs of these conditions are not well understood. Noticeably, there are no licensed treatments available for other forms of angioedema beyond HAE types I/II, and similarly they are unresponsive to conventional antihistamine/glucocorticoid treatment. A group of angioedema experts met in Budapest in May 2013 to discuss such issues, presenting their experience, reviewing available literature and identifying unmet diagnostic and treatment needs in three different angioedema types: HAE with normal C1-inhibitor (C1-INH; previously referred to as type III HAE); nonallergic angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema (ACEI-AAE), and acquired angioedema due to C1-INH deficiency (C1-INH-AAE). The group identified unmet diagnostic and treatment needs in HAE-nC1-INH, C1-INH-AAE and ACEI-AAE, explored remedies and made recommendations on how to diagnose and treat these forms of angioedema. The group discussed the difficulties associated with using diagnostic markers, such as the level and function of C1-INH, C1q and C4 to reliably diagnose the angioedema type, and considered the use of genetic testing to identify mutations in FXII or XPNPEP2 that have been associated with HAE-nC1-INH and ACEI-AAE, respectively. Due to the lack of approved treatments for HAE-nC1-INH, ACEI-AAE and C1-INH-AAE, the group presented several case studies in which therapies approved for treatment of HAE types I/II, such as icatibant, ecallantide and pasteurized, nanofiltered C1-INH, were successful. It was uniformly agreed that further studies are needed to improve the diagnosis and treatment of angioedema other than HAE types I/II.",
keywords = "Angioedema, C1 inhibitor, C1-esterase inhibitor, Hereditary angioedema, Treatment",
author = "Craig, {Timothy J.} and Bernstein, {Jonathan A.} and H. Farkas and Laurence Bouillet and Isabelle Boccon-Gibod",
year = "2014",
month = "12",
day = "25",
doi = "10.1159/000368404",
language = "English",
volume = "165",
pages = "119--127",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Diagnosis and treatment of bradykinin-mediated angioedema

T2 - Outcomes from an angioedema expert consensus meeting

AU - Craig, Timothy J.

AU - Bernstein, Jonathan A.

AU - Farkas, H.

AU - Bouillet, Laurence

AU - Boccon-Gibod, Isabelle

PY - 2014/12/25

Y1 - 2014/12/25

N2 - Several types of angioedema exist beyond hereditary angioedema (HAE) types I/II; however, the diagnostic and treatment needs of these conditions are not well understood. Noticeably, there are no licensed treatments available for other forms of angioedema beyond HAE types I/II, and similarly they are unresponsive to conventional antihistamine/glucocorticoid treatment. A group of angioedema experts met in Budapest in May 2013 to discuss such issues, presenting their experience, reviewing available literature and identifying unmet diagnostic and treatment needs in three different angioedema types: HAE with normal C1-inhibitor (C1-INH; previously referred to as type III HAE); nonallergic angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema (ACEI-AAE), and acquired angioedema due to C1-INH deficiency (C1-INH-AAE). The group identified unmet diagnostic and treatment needs in HAE-nC1-INH, C1-INH-AAE and ACEI-AAE, explored remedies and made recommendations on how to diagnose and treat these forms of angioedema. The group discussed the difficulties associated with using diagnostic markers, such as the level and function of C1-INH, C1q and C4 to reliably diagnose the angioedema type, and considered the use of genetic testing to identify mutations in FXII or XPNPEP2 that have been associated with HAE-nC1-INH and ACEI-AAE, respectively. Due to the lack of approved treatments for HAE-nC1-INH, ACEI-AAE and C1-INH-AAE, the group presented several case studies in which therapies approved for treatment of HAE types I/II, such as icatibant, ecallantide and pasteurized, nanofiltered C1-INH, were successful. It was uniformly agreed that further studies are needed to improve the diagnosis and treatment of angioedema other than HAE types I/II.

AB - Several types of angioedema exist beyond hereditary angioedema (HAE) types I/II; however, the diagnostic and treatment needs of these conditions are not well understood. Noticeably, there are no licensed treatments available for other forms of angioedema beyond HAE types I/II, and similarly they are unresponsive to conventional antihistamine/glucocorticoid treatment. A group of angioedema experts met in Budapest in May 2013 to discuss such issues, presenting their experience, reviewing available literature and identifying unmet diagnostic and treatment needs in three different angioedema types: HAE with normal C1-inhibitor (C1-INH; previously referred to as type III HAE); nonallergic angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema (ACEI-AAE), and acquired angioedema due to C1-INH deficiency (C1-INH-AAE). The group identified unmet diagnostic and treatment needs in HAE-nC1-INH, C1-INH-AAE and ACEI-AAE, explored remedies and made recommendations on how to diagnose and treat these forms of angioedema. The group discussed the difficulties associated with using diagnostic markers, such as the level and function of C1-INH, C1q and C4 to reliably diagnose the angioedema type, and considered the use of genetic testing to identify mutations in FXII or XPNPEP2 that have been associated with HAE-nC1-INH and ACEI-AAE, respectively. Due to the lack of approved treatments for HAE-nC1-INH, ACEI-AAE and C1-INH-AAE, the group presented several case studies in which therapies approved for treatment of HAE types I/II, such as icatibant, ecallantide and pasteurized, nanofiltered C1-INH, were successful. It was uniformly agreed that further studies are needed to improve the diagnosis and treatment of angioedema other than HAE types I/II.

KW - Angioedema

KW - C1 inhibitor

KW - C1-esterase inhibitor

KW - Hereditary angioedema

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84911499704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911499704&partnerID=8YFLogxK

U2 - 10.1159/000368404

DO - 10.1159/000368404

M3 - Article

C2 - 25401373

AN - SCOPUS:84911499704

VL - 165

SP - 119

EP - 127

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 2

ER -